Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma - PharmaTimes More than 71% of patients treated with Unloxcyt achieved disease control

#oncology #generics #SunPharma #Unloxcyt #cosibelimab #CSCC #squamouscellcarcinoma #mCSCC #SCC #laCSCC #FDA #CK301101 #clinicaltrial #skincancer #headandneckcancer #checkpointinhibition #checkpointinhibitor

pharmatimes.com/news/sun-pha...

FDA Approves UNLOXCYT™ Label Update, Enhancing Treatment for Advanced Skin Cancer The FDA has updated the label for UNLOXCYT™, an innovative treatment for advanced squamous cell carcinoma, showcasing improved outcomes based on long-term data.

FDA Approves UNLOXCYT™ Label Update, Enhancing Treatment for Advanced Skin Cancer #United_States #Princeton #UNLOXCYT #cosibelimab #squamous_cell

#Cosibelimab is anti-PD-L1 therapy for the treatment of adults with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation. In contrast to anti-PD-L1 antibodies, cosibelimab can induce antibody-dependent cell mediated cytotoxicity as it incl a functional Fc domain

Oncology Brothers: 6 new drugs in Skin Cancer, Thyroid Cancer, Sarcoma and Glioma by U.S. FDA - OncoDaily Oncology Brothers: 6 new drugs in Skin Cancer, Thyroid Cancer, Sarcoma and Glioma by U.S. FDA / AfamiCel, cancer, Cosibelimab, glioma, Lifileucel, OncoDaily,

6 new drugs in Skin Cancer, Thyroid Cancer, Sarcoma and Glioma by U.S. FDA - Oncology Brothers
@fda.gov
@oncbrothers.bsky.social

oncodaily.com/blog/oncolog...

#AfamiCel #Cancer #Cosibelimab #Glioma #Lifileucel #OncoDaily #Oncology #Sarcoma #Selpercatinib #SkinCancer #FDA #Vorasidenib